Total and Cardiovascular Disease Mortality Predicted by Metabolic Syndrome is Inferior Relative to its Components

Abstract

Objectives: This study examined the predictive role of metabolic syndrome (MetS) and its single components for total and cardiovascular disease (CVD) mortality.

Methods: We analyzed data from 3 927 participants aged 20–79 years without history of CVD, recruited for the prospective population-based Study of Health in Pomerania (SHIP). During the mean 7.2 years (25^th, 6.6; 75^th: 8.0) of follow-up, 240 deaths (79 CVD deaths) occurred. MetS was defined by National Cholesterol Education Program Adult Treatment Panel III guidelines. The association of MetS with total and CVD mortality was analyzed by Cox proportional hazards regression models. The impact of single MetS components on survival time was compared using standardized beta coefficients from multivariable linear regression models.

Results: Baseline MetS prevalence was 28.8%. Age- and gender-adjusted Cox models revealed that participants with MetS had an increased risk of total mortality (hazard ratio (HR) 1.41; 95% confidence interval (95% CI) 1.09–1.82) and CVD mortality (HR 1.82; 95% CI 1.22–3.13) compared to participants without MetS. Of the single MetS components, participants with increased waist circumference (WC) and glucose levels exposed highest risk of total (HR 1.49; 95% CI 1.10–2.01; HR 2.13; 95% CI 1.58–2.90, respectively) and CVD mortality (HR 2.02; 95% CI 1.13–3.61; HR 3.15; 95% CI 1.94–5.11, respectively). Increasing WC or glucose by 1 standard deviation (SD) significantly decreased age- and gender-adjusted beta coefficients for survival time by 0.09, and 0.08 SD, respectively.

Conclusion: There was no added predictive value of MetS beyond its individual components with respect to mortality risk. Attention should be redirected to the individual components, particularly visceral obesity and high glucose, to treat each abnormality appropriately.

metabolic syndrome - mortality - population-based cohort - SHIP

References

• 1 Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world – a growing challenge.  The New England journal of medicine. 2007;  356 213-215
• 2 Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome.  Lancet. 2005;  365 1415-1428
• 3 James PT, Rigby N, Leach R. The obesity epidemic, metabolic syndrome and future prevention strategies.  Eur J Cardiovasc Prev Rehabil. 2004;  11 3-8
• 4 Jorgensen ME, Borch-Johnsen K. The metabolic syndrome – is one global definition possible?.  Diabet Med. 2004;  21 1064-1065
• 5 Kahn R, Buse J, Ferrannini E. et al . The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.  Diabetes care. 2005;  28 2289-2304
• 6 Sattar N. Why metabolic syndrome criteria have not made prime time: a view from the clinic.  International journal of obesity (2005). 2008;  32 (S 02) S30-S34
• 7 Sattar N, McConnachie A, Shaper AG. et al . Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from 2 prospective studies.  Lancet. 2008;  371 1927-1935
• 8 Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence.  Diabetes Care. 2008;  31 1898-1904
• 9 El Bassuoni EA, Ziemer DC, Kolm P. et al . The “metabolic syndrome” is less useful than random plasma glucose to screen for glucose intolerance.  Primary care diabetes. 2008;  2 147-153
• 10 Greenland P. Critical questions about the metabolic syndrome.  Circulation. 2005;  112 3675-3676
• 11 Iribarren C, Go AS, Husson G. et al . Metabolic syndrome and early-onset coronary artery disease: is the whole greater than its parts?.  Journal of the American College of Cardiology. 2006;  48 1800-1807
• 12 Kahn R. Metabolic syndrome – what is the clinical usefulness?.  Lancet. 2008;  371 1892-1893
• 13 Reaven GM. The metabolic syndrome: is this diagnosis necessary?.  The American journal of clinical nutrition. 2006;  83 1237-1247
• 14 Wilson PW, D’Agostino RB, Parise H. et al . Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus.  Circulation. 2005;  112 3066-3072
• 15 Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. 1988.  Nutrition (Burbank, Los Angeles County, Calif 13:65; discussion 64, 66) 1997; 
• 16 Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.  Diabet Med. 1998;  15 539-553
• 17 Moebus S, Stang A. The metabolic syndrome – a controversial diagnostic concept.  Herz. 2007;  32 529-540
• 18 Isomaa B, Almgren P, Tuomi T. et al . Cardiovascular morbidity and mortality associated with the metabolic syndrome.  Diabetes care. 2001;  24 683-689
• 19 Bonora E, Targher G, Formentini G. et al . The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study.  Diabet Med. 2004;  21 52-58
• 20 Lakka HM, Laaksonen DE, Lakka TA. et al . The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.  JAMA. 2002;  288 2709-2716
• 21 Sattar N, Gaw A, Scherbakova O. et al . Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study.  Circulation. 2003;  108 414-419
• 22 Lorenzo C, Okoloise M, Williams K. et al . The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study.  Diabetes care. 2003;  26 3153-3159
• 23 Mozaffarian D, Kamineni A, Prineas RJ. et al . Metabolic syndrome and mortality in older adults: the Cardiovascular Health Study.  Archives of internal medicine. 2008;  168 969-978
• 24 Bruno G, Merletti F, Biggeri A. et al . Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study.  Diabetes care. 2004;  27 2689-2694
• 25 Niwa Y, Ishikawa S, Gotoh T. et al . Metabolic syndrome mortality in a population-based cohort study: Jichi Medical School (JMS) Cohort Study.  Journal of epidemiology/Japan Epidemiological Association. 2007;  17 203-209
• 26 Gami AS, Witt BJ, Howard DE. et al . Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies.  Journal of the American College of Cardiology. 2007;  49 403-414
• 27 Volzke H, Alte D, Schmidt CO. et al . Cohort Profile: The Study of Health in Pomerania.  International journal of epidemiology. 2010 Feb 18 (Epub ahead of print); 
• 28 Alte D, Luedemann J, Rose HJ. et al . Laboratory markers carbohydrate-deficient transferrin, gamma-glutamyltransferase, and mean corpuscular volume are not useful as screening tools for high-risk drinking in the general population: results from the Study of Health in Pomerania (SHIP).  Alcoholism, clinical and experimental research. 2004;  28 931-940
• 29 Winkler G, Doring A. Validation of a short qualitative food frequency list used in several German large scale surveys.  Zeitschrift fur Ernahrungswissenschaft. 1998;  37 234-241
• 30 WHO .Measuring obesity – classification and description of anthropometric data. Report on a WHO consultation of the epidemiology of obesity. In: Warsaw, 21–23 October 1987.
• 31 Third Report of the National Cholesterol Education Program (NCEP) . Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.  Circulation. 2002;  106 3143-3421
• 32 Grundy SM, Cleeman JI, Daniels SR. et al . Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.  Circulation. 2005;  112 2735-2752
• 33 Lidfeldt J, Nyberg P, Nerbrand C. et al . Socio-demographic and psychosocial factors are associated with features of the metabolic syndrome. The Women's Health in the Lund Area (WHILA) study.  Diabetes, obesity & metabolism. 2003;  5 106-112
• 34 Haheim LL, Holme I, Sogaard AJ. et al . Changes in cardiovascular risk factors among men in Oslo during 28 years.  Tidsskrift for den Norske laegeforening. 2006;  126 2240-2245
• 35 Kleinbaum DG. Survival Analysis: A Self-Learning Text (Statistics for Biology and Health): Springer; 2nd ed. 2005; 
• 36 Rathmann W, Haastert B, Icks A. et al . Prevalence of the metabolic syndrome in the elderly population according to IDF, WHO, and NCEP definitions and associations with C-reactive protein: the KORA Survey 2000.  Diabetes care. 2006;  29 461
• 37 Neuhauser H, Ellert U. Estimation of the metabolic syndrome prevalence in the general population in Germany. In: Journal of Public Health 2007
• 38 Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.  JAMA. 2002;  287 356-359
• 39 Hildrum B, Mykletun A, Hole T. et al . Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: the Norwegian HUNT 2 study.  BMC public health. 2007;  7 220
• 40 Laaksonen DE, Lakka HM, Niskanen LK. et al . Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study.  American journal of epidemiology. 2002;  156 1070-1077
• 41 Otiniano ME, Du XL, Maldonado MR. et al . Effect of metabolic syndrome on heart attack and mortality in Mexican-American elderly persons: findings of 7-year follow-up from the Hispanic established population for the epidemiological study of the elderly.  The journals of gerontology. 2005;  60 466-470
• 42 Hunt KJ, Resendez RG, Williams K. et al . National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study.  Circulation. 2004;  110 1251-1257
• 43 Dekker JM, Girman C, Rhodes T. et al . Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study.  Circulation. 2005;  112 666-673
• 44 Pepe MS, Janes H, Longton G. et al . Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker.  American journal of epidemiology. 2004;  159 882-890
• 45 McNeill AM, Rosamond WD, Girman CJ. et al . The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study.  Diabetes care. 2005;  28 385-390
• 46 Stern MP, Williams K, Gonzalez-Villalpando C. et al . Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease?.  Diabetes care. 2004;  27 2676-2681
• 47 Wannamethee SG, Shaper AG, Lennon L. et al . Metabolic syndrome vs. Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus.  Archives of internal medicine. 2005;  165 2644-2650
• 48 Pischon T, Boeing H, Hoffmann K. et al . General and abdominal adiposity and risk of death in Europe.  The New England journal of medicine. 2008;  359 2105-2120
• 49 Staessen JA, Gasowski J, Wang JG. et al . Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials.  Lancet. 2000;  355 865-872
• 50 Pastor-Barriuso R, Banegas JR, Damian J. et al . Systolic blood pressure, diastolic blood pressure, and pulse pressure: an evaluation of their joint effect on mortality.  Annals of internal medicine. 2003;  139 731-739
• 51 Blacher J, Staessen JA, Gired X. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients.  Archives of internal medicine. 2000; 
• 52 Wang J, Ruotsalainen S, Moilanen L. et al . The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns.  European heart journal. 2007;  28 857-864
• 53 Hu G, Qiao Q, Tuomilehto J. et al . Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women.  Archives of internal medicine. 2004;  164 1066-1076

Correspondence